SARS-CoV-2, the virus responsible for the COVID-19 pandemic, causes a range of respiratory symptoms that can vary from mild to severe. In some individuals, the infection results in only mild upper respiratory symptoms, such as a sore throat or mild cough. However, in other cases, especially among vulnerable populations, it can lead to severe respiratory distress, requiring hospitalization, intensive care, or even resulting in death. The virus primarily spreads through respiratory droplets, and early detection is key to preventing transmission and ensuring timely treatment. The impact of SARS-CoV-2 on global health has made rapid and reliable testing crucial in the effort to contain the pandemic.

The SARS-CoV-2 Rapid Antigen Test is an immunochromatographic assay designed to detect the presence of SARS-CoV-2 in individuals suspected of infection. This test works by identifying specific Nucleocapsid (N) proteins unique to the SARS-CoV-2 virus in swab specimens taken from the nose or throat. Unlike traditional PCR tests, which may take longer to process, the SARS-CoV-2 Rapid Antigen Test provides results in as little as 10-15 minutes, making it an essential tool for rapid screening in healthcare settings, airports, schools, and other public spaces.

One of the primary benefits of the SARS-CoV-2 Rapid Antigen Test is its ability to deliver fast, reliable results. In cases where the test is positive, healthcare professionals can initiate treatment immediately, which is crucial for individuals who may be at high risk of developing severe symptoms. Early detection also allows for quicker isolation of infected individuals, reducing the spread of the virus within communities. Moreover, the simplicity and speed of the test make it a vital tool for mass testing efforts, helping to detect asymptomatic carriers and prevent outbreaks.

This test provides a cost-effective and accessible solution for COVID-19 detection, complementing PCR testing by enabling rapid diagnosis and early intervention. It is especially useful in areas where timely results are needed to make quick decisions about isolation or treatment. While PCR tests remain the gold standard for COVID-19 diagnosis, the SARS-CoV-2 Rapid Antigen Test plays a critical role in controlling the spread of the virus by providing quick, accurate results that can inform public health responses in real time.

Sample types: nasopharyngeal and oropharyngeal swabs

Sensitivity: 99.5 %

Specificity: 99.5%

LoD: 500-4000 cp/mL

Q-Check SARS-CoV-2 Rapid Antigen Test                              25T/Box                    QCH-0002-25

                                                                              Single Test/Box                    QCH-0002-1